Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murepavadin plus one antipseudomonal antibiotic versus two antipseudomonal antibiotics for ventilator-associated bacterial pneumonia due to Pseudomonas aeruginosa
2017-003933-27Phase 3Terminated
- Sponsor
- Polyphor
- Start
- Dec 2017
- Modality
- Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of murepavadin in ventilator-associated pneumonia (VAP) and Pseudomonal infection (2 arms), sponsored by Polyphor. Primary endpoint: Clinical cure rate at test-of-cure. Started Dec 2017; status: terminated.
02
Drugs
murepavadin
03
Conditions
ventilator-associated pneumonia (VAP)Pseudomonal infection
Beyond the preview
Go deeper on 2017-003933-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003933-27.